Agenda

11:30 AM – 12:00 PM Registration, Networking & Lunch*

12:00 PM – 1:00 PM    Presentation & Q&A;

1:00 PM – 2:00 PM      Networking Dessert & Product Show

*Lunch will be provided

Overview

Gary Baker, Managing Director of the Quine IP Law Group, will discuss recent court cases, which effectively narrow the scope of acceptable subject matter for patent protection. In Mayo v. Prometheus (U.S. Supreme Court, No. 10–1150, argued December 7, 2011 – decided March 20, 2012), the relationship between serum thiopurine metabolite levels and the efficacy or toxicity of dosing was deemed an unpatentable law of nature. The Supreme Court held that simply appending conventional steps, specified at high level of generality, to laws of nature does not provide patentable subject matter.

Mr. Baker will discuss the history leading to Prometheus and possible practical effects with regard to analytical and treatment methods claims.

Immediately following the event, the BioCenter will host a Networking Dessert & Product Show, generously provided by Scientist Solutions Events. All attendees and BioCenter clients are invited to come out to enjoy food/refreshments/espresso bar/raffle and browse the vendor tables!

Cost & Registration

Register now! • Regular Price: $35**

• Partners’ Network: $25**

• BioCenter Members: Free

• On-site Registration, if space allows: same cost but bring your lunch…

**Register before Tuesday June 26th!

This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Venue

San Jose BioCenter

5941 Optical Court

Second Floor

San Jose, CA 95138

China: Integrated IND-Enabling Support with a Sole Source Provider – ariva medical

Agenda

11:30 AM – 12:00 PM  Registration & Networking

12:00 PM – 1:00 PM    Presentation & Q&A;

*Lunch provided

Overview

As research and development costs continue to rise, it is evident that outsourcing will become an important part of the competitive landscape. This next step in the evolution of the biopharmaceutical industry signals that companies are now looking for more value, expertise, and innovation within their outsourcing options. With many analysts predicting China to become an essential location for outsourcing, how can a company stay well-informed?

This Lunch & Learn features Pharmaron, a premier R&D; service provider for the pharmaceutical industry with resources in China. With their expertise, you will learn the intricacies of outsourcing development programs to China, what key considerations to keep in mind, and how best to manage this process. Accessing this knowledge will allow you to make the strategic, coherent decisions that will add value and a competitive advantage to your company.

Various topics include:

    What are the main benefits of outsourcing your preclinical programs to China?

    What are the challenges to oursourcing and how to avoid them?

    What capabilities should you outsource? Which should you maintain in-house?

Speakers

Tina Huang, Ph.D. – Senior VP, IND-Enabling Services, Pharmaron

Dr. Huang has over 16 years of experience in the life science and financial fields including former Senior Vice President of Operations at the Preclinical Services facility at Pharmaron. Recently, Dr. Huang has been instrumental in establishing Pharmaron’s IND-enabling and integrated platform of services. Dr. Huang earned her Ph.D. degree from State University of New York in Molecular Biology and Biochemistry.

Connie Sun, Ph.D. – Senior VP, Oncology Chemistry, Pharmaron

Dr. Sun joined Pharmaron in 2009 as Senior VP of Oncology Services and has over 16 years of biopharmaceutical experience. Prior to joining Pharmaron, Dr. Sun held the positions of Senior Director of Chemistry at Poniard Pharmaceuticals, Inc., Senior Director of Chemistry at AGY Therapeutics and Director of Chemistry at SUGEN (Pharmacia/Pfizer). She graduated from Beijing Medical University, China (Peking University) with a B.S. in Medicinal Chemistry and holds a Ph.D. in Medicinal Chemistry from the University of North Carolina, Chapel Hill.

Allison Perkins, M.S. – Executive Director, Business Development (Preclinical Services), Pharmaron

Ms. Perkins joined Pharmaron in 2010 as part of the acquisition of the Bridge Laboratories GLP facility in China. She continues to lead the toxicology business development efforts at Pharmaron. She earned her B.S. degree in Biology from Villanova University and her M.S. degree in Animal Science from Purdue University.

About Pharmaron

Pharmaron is the premier integrated drug R&D; service provider in China. Pharmaron has strong leadership in the area of IND-enabling services, which encompasses GMP synthesis, development DMPK, development pharmacology, GLP-toxicology and GLP-safety pharmacology.

The rise of Big Pharma VC Funds: Dream coming true or total nightmare? – ariva medical

Agenda

3:00 PM – 3:30 PM      Registration & Networking

3:30 PM – 5:00 PM      Industry Panel

5:00 PM – 6:30 PM      Networking Reception

Overview

It seems like a new Big Pharma Venture arm appears every week or so. Is this just a new trend or are they here for good? How are these Corporate VCs different than traditional VCs? Do they have the same objectives, the same investment criteria, or the same strategies? Or are they definitely two very different things? What does this mean for all the emerging companies out there? Are traditional VCs doomed to disappear? Are these new players a nightmare to deal with in day to day management and operations of your company?

Join us at our next industry panel for an interactive discussion on why and how corporate players are getting in the game and hitting it big! Furthermore, our expert panelists will provide their own insight on the current trends shaping their industry as well as their future predictions on where it is headed.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Panelists (Partial list)

• James Schaeffer, Ph.D., Executive Director, Worldwide Licensing and External Research, Merck Research Laboratories

• Jennifer Friel Goldstein, Director, Pfizer Venture Investment

• Brad Vale, Ph.D., DVM, Vice President, Head of Venture Investments, Johnson & Johnson Development Corporation (JJDC) (TBC)

• Lead Facilitator: Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP

More information coming soon!

Cost & Registration

Register now! • General Ticket: $60

• Partners’ Network: $50

• Meet with Alumni: $40

• BioCenter Members: Free (please RSVP to Aurιlie)

• On-site Registration: add $10 to the above

This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Venue

Orrick, Herrington & Sutcliffe LLP

1100 Marsh Rd.

Menlo Park, CA 94025

Panelists Bios

James Schaeffer, Ph.D., Executive Director, Worldwide Licensing and External Research, Merck Research Laboratories

Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of four major agreements. Jim moved to San Diego in 2004 to assume the role of Merck’s “Science Scout” on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the past eight years, Jim has been directly involved in the execution of 14 major agreements with West Coast based organizations including recent agreements with AmbrX, Marcadia, BioAtla, the University of California in San Francisco and the University of Texas-Southwestern.

As of July 2008, Jim is also responsible for Merck’s scouting efforts in China. Jim has also been directly involved in the establishment of a Merck-funded research institute (The California Institute for Biomedical Research- Calibr) in La Jolla, California. Calibr will focus on the advancement of early stage innovative research through animal proof of concept.

Dr. Schaeffer received his PhD at Baylor College of Medicine and was a post-doctoral fellow in the laboratory of Dr Julius Axelrod at the National Institute of Mental Health. He is the author of more than 110 articles in peer reviewed journals.

Jennifer Friel Goldstein, Director, Pfizer Venture Investment

Jennifer Friel Goldstein, BSE/MB/MBA is a Director on Pfizer’s Venture Investments team. She is responsible for new investments as well as managing Pfizer’s legacy $250M private equity portfolio. Jennifer brings ten years of business development, portfolio management, and consulting experience as well as a biotechnology background to the team.

Jennifer joined Pfizer as part of the Portfolio and Decision Analysis group, where she led commercial and business development projects. While a consultant at Bain & Company, Jennifer focused on private equity deals. She has also had diverse internship experience at companies such as Chiron, Genelabs, and Genencor.

Jennifer is a board observer to Ablexis and board member of the New York Venture Capital Association. She graduated magna cum laude with a BSE in Bioengineering and a Master’s of Biotechnology from the University of Pennsylvania. Jennifer was also named a Joseph Wharton Fellow while completing her MBA at the Wharton school.

Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP

Scott Iyama is a member of the Emerging Companies Group, which advises high growth companies and venture capital firms. Scott’s practice includes the formation, financing and general corporate counseling of emerging growth private and public companies; representation of venture capital firms and investment banks in private and public offerings; and other strategic transactions. Scott has completed hundreds of private financings and numerous mergers, acquisitions and licensing transactions. Prior to receiving his J.D. from Stanford Law School, Scott performed extensive biochemical research at the University of California, San Diego, and Genentech, Inc., and was a research intern at the NASA Ames Research Center.